Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
|25 Mar 2021||$1.1500||0.00%||Interim||20 Apr 2021|
|19 Sep 2019||$1.7500||100.00%||Final||14 Oct 2019|
|25 Mar 2019||$1.5500||100.00%||Interim||16 Apr 2019|
|17 Sep 2018||$1.6000||100.00%||Final||10 Oct 2018|
|19 Mar 2018||$1.4000||100.00%||Interim||12 Apr 2018|
|19 Sep 2017||$1.4000||100.00%||Final||11 Oct 2017|
|15 Mar 2017||$1.3000||100.00%||Interim||06 Apr 2017|
|07 Sep 2016||$1.2000||100.00%||Final||29 Sep 2016|
|10 Mar 2016||$1.1000||100.00%||Interim||01 Apr 2016|
|08 Sep 2015||$1.0000||100.00%||01 Oct 2015|
|03 Mar 2015||$0.9000||35.00%||26 Mar 2015|
|02 Sep 2014||$1.2700||20.00%||Final||25 Sep 2014|
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Cochlear Limited (COH) is a global leader in implantable hearing devices. The company manufactures and distributes cochlear implantable devices for hearing impaired.
Based in Sydney, Cochlear has operations in more than 20 countries, distributing its products in America, Asia Pacific, Europe, the Middle East and Africa. It offers three main products: Cochlear implants, Baha bone conduction implants and Cochlear Wireless Accessories.
Cochlear was formed in 1981, with COH shares first listing on the ASX almost 15 years later in 1995. Since then, the Cochlear share price has risen exponentially and the company is now one of the largest-listed companies on the ASX.
|22 Sep 2021||$236.03||$-0.45||-0.19%||75,775||$236.38||$237.78||$234.50|
|21 Sep 2021||$236.48||$1.61||0.69%||96,692||$234.87||$237.57||$232.47|
|20 Sep 2021||$234.87||$-3.41||-1.43%||66,858||$238.03||$238.60||$234.57|
|17 Sep 2021||$238.28||$0.16||0.07%||246,631||$240.20||$240.37||$237.00|
|16 Sep 2021||$238.12||$3.40||1.45%||175,860||$237.98||$239.47||$234.61|
|15 Sep 2021||$234.72||$4.72||2.05%||124,405||$231.00||$236.36||$229.22|
|14 Sep 2021||$230.00||$-1.20||-0.52%||124,840||$231.54||$234.36||$227.52|
|13 Sep 2021||$231.20||$-1.52||-0.65%||108,571||$233.48||$234.82||$229.58|
|10 Sep 2021||$232.72||$-4.00||-1.69%||132,647||$238.88||$239.95||$232.01|
|09 Sep 2021||$236.72||$-2.52||-1.05%||105,295||$239.00||$240.20||$235.50|
|08 Sep 2021||$239.24||$-4.45||-1.83%||149,616||$243.00||$244.38||$238.71|
|07 Sep 2021||$243.69||$4.80||2.01%||280,711||$239.27||$244.60||$238.89|
|06 Sep 2021||$238.89||$1.53||0.64%||132,714||$234.85||$238.89||$231.00|
|03 Sep 2021||$237.36||$4.82||2.07%||157,037||$233.20||$238.49||$233.16|
|02 Sep 2021||$232.54||$1.24||0.54%||126,138||$232.79||$234.08||$228.43|
|01 Sep 2021||$231.30||$-1.90||-0.81%||95,594||$232.28||$232.85||$229.56|
|31 Aug 2021||$233.20||$4.44||1.94%||180,849||$229.50||$234.83||$229.06|
|30 Aug 2021||$228.76||$1.91||0.84%||105,796||$226.86||$229.50||$226.20|
|27 Aug 2021||$226.85||$-1.44||-0.63%||167,621||$225.35||$227.28||$222.62|
|26 Aug 2021||$228.29||$-0.93||-0.41%||115,419||$229.22||$230.49||$226.60|
|25 Aug 2021||$229.22||$-7.47||-3.16%||188,964||$238.00||$238.00||$229.02|
|24 Aug 2021||$236.69||$-4.86||-2.01%||161,305||$241.47||$241.97||$236.69|
|07 Sep 2021||Dig Howitt||Sell||8||$2,132,934||
|03 Sep 2021||Dig Howitt||Exercise||8||$1,823,734||
Exercise of options.
|03 Sep 2021||Dig Howitt||Buy||8||$1,823,734||
Exercise of options.
|25 Aug 2021||Christine McLoughlin||Buy||232||$53,617||
|23 Aug 2021||Dig Howitt||Cancelled||1||$305,319||
Cancellation of securities. 9,214 - Performance Rights
|23 Aug 2021||Dig Howitt||Buy||3||$737,935||
Conversion of securities.
|23 Aug 2021||Dig Howitt||Cancelled||26||$6,501,559||
Cancellation of securities.
|23 Aug 2021||Dig Howitt||Exercise||3||$737,935||
Conversion of securities. 10,478 - Performance Rights
|23 Aug 2021||Christine McLoughlin||Buy||168||$40,671||
|26 Feb 2021||Catriona Deans||Buy||786||$163,825||
|21 Oct 2020||Dig Howitt||Issued||4||$1,062,703||
Issue of securities. 13,533 - Performance Rights
|21 Oct 2020||Dig Howitt||Issued||21||$4,715,053||
Issue of securities.
|Ms Christine Frances McLoughlin||Non-Executive Director||Nov 2020||
Ms McLoughlin has served on the boards of a number of ASX50 companies and is a company director with domestic and international experience. She has had wide ranging experience covering health, insurance, resources, infrastructure and financial services. In June 2021, Ms McLoughlin was awarded a Member of the Order of Australia in the Queen's Birthday Honours for her services to business, the not-for-profit sector and women. Other boards includes Chairman of the Suncorp Group Limited, Chancellor of the University of Wollongong. Chairman, Destination NSW. Australian Private Sector Representative, G20 EMPOWER Council. Former directorships includes NIB Holding, the McGrath Foundation and Venues NSW. She is member of Risk, People & Culture Committees.
|Mr Michael Grenfell Daniell||Non-Executive Director||Jan 2020||
Mr Daniell has 40 years experience in the medical device industry with executive leadership experience. Former Managing Director and CEO of Fisher & Paykel Healthcare Corporation Limited responsible for the global business and operations including the design, manufacture and marketing of innovative products and systems for use in respiratory care, acute care and treatment of obstructive sleep apnea. In June 2021, Sir Michael was made a Knight Companion of the New Zealand Order of Merit for his services to business, healthcare and governance. Other boards includes Director, Fisher & Paykel Healthcare Corporation Ltd, Council member, The University of Auckland, Director, Tait International Limited, Chair, New Zealand Medical Technology Centre of Research Excellence, Director, Medical Research Commercialisation Fund. He is Chair of Technology & Innovation Committee effective 20 August 2021. Member of the Medical Science and Technology & Innovation Committees.
|Ms Catriona Alison Deans||Non-Executive DirectorNon-Executive Chairman||Jan 2015||
Ms Deans have experience leading technology enabled businesses across ecommerce, media and financial services. Former Chief Executive Officer of netus, Hoyts Cinemas, ecorp and eBay Australia and New Zealand. Other boards includes Director, Ramsay Health Care Limited and Deputy Group Pty Ltd. Senior Advisor to McKinsey & Company. Member of Investment Committee, CSIRO Innovation fund (MainSequence Ventures) and member of AICD Corporate Governance Committee. Director of SCEGGS Darlinghurst Limited and The Observership Program. Former directorships includes Westpac Banking Corporation, Insurance Australia Group Limited and Social Ventures Australia. She is Chair Technology & Innovation Committee until 19 August 2021. Member of the Risk and People & Culture Committees.
|Mr Andrew Leslie Denver||Non-Executive Director||Feb 2007||
Mr Denver have experience in the life sciences industry. Former Managing Director of Memtec Limited and President Asia for Pall Corporation. He is Chairman of SpeeDx and Director, Vaxxas and QBiotics and was Executive Chairman of Universal Biosensors. He is member of Risk, Medical Science, Technology & Innovation and Committees.
|Ms Yasmin Anita Allen||Non-Executive Director||Aug 2010||
Ms Allen has career in investment banking with senior roles in strategic analysis and corporate advice. Former Vice President of Deutsche Bank AG, Director of ANZ Investment Bank and Associate Director of HSBC London. She is also Chair of Australian Federal Government Steering Group for Digital Skills Organisation. She is Director of Santos Limited, ASX Limited and National Portrait Gallery. Member of the George Institute for Global Health Board. Chairman, Advance (Global Australian Network), Acting President, Australian Government Takeovers Panel and Chairman of Faethm.org. She is Chair of the Risk Committee, Member of the People & Culture and Technology & Innovation Committees. She was director of Insurance Australia Group Limited, National director of the Australian Institute of Company Directors, Member of The Salvation Army Advisory Board. Chair of Macquarie Specialised Asset Management.
|Mr Glen Francis Boreham||Non-Executive Director||Jan 2015||
Mr Boreham led organisations in information technology, new media and the creative industries through periods of rapid change and innovation. Former Managing Director of IBM Australia and New Zealand. He is Director of Southern Cross Media Group and Link Group and Strategic Advisor of IXUP. He was director of Data#3. Chairman of Screen Australia, Advance (Global Australian Network), Business School and Industry Advisory Board for the University of Technology, Sydney and Advisory Board IXUP. He is Chair of the People & Culture Committee. Member of the Risk and Technology & Innovation Committees.
|Professor Bruce Gregory Robinson||Non-Executive Director||Dec 2016||
Prof Robinson have 20 years leadership experience as an academic physician/scientist across research, healthcare and medicine, and tertiary education. Former Dean of The University of Sydney's Sydney Medical School, Head of Medicine at Sydney's Royal North Shore Hospital and Head of the Cancer Genetics Laboratory at the Kolling Institute for Medical Research. Other boards includes Chairman, National Health and Medical Research Council. Director, MaynePharma, QBiotocs and Ecofibre. Director, Woolcock Institute of Medical Research and Senior Advisor to McKinsey & Company and MinterEllison. Former directorships includes Chairman, Medical Benefits Schedule Review Taskforce. Director, Lorica Health Pty Limited, Firefly and Digital Health Agency CRC. He is Chair of Medical Science Committee. Member of the People & Culture and Technology & Innovation Committees.
|Mr Dig Howitt||PresidentChief Executive OfficerManaging Director||Jul 2017||
Mr Howitt has experience across the Company in roles including Chief Operating Officer, SVP, Manufacturing and Logistics and President, Asia Pacific. Prior to joining Cochlear, worked for Boral and Boston Consulting Group. Dig is a member of the Champions of Change STEM group. He is Member of the Medical Science and Technology & Innovation Committees. He is Director of QPBT Pty Ltd.
|Mr Ray Jarman||Company Secretary||Feb 2017||
|Stu Sayers||Chief Financial Officer||
|David Hackshall||Chief Information Officer||
|Jan Janssen||Chief Technology Officer||
|Ray Jarman||Company Secretary||
|Tony Manna||President Americas Region||
|Anthony Bishop||President Asia Pacific Region||
|Richard Brook||President EMEA & Latin American Region||
|Brian Kaplan||Senior Vice President Clinical Strategy and Innovation||
|Dean Phizacklea||Senior Vice President Global Strategic Marketing||
|Jennifer Hornery||Senior Vice President People & Culture||
|Greg Bodkin||Senior Vice President Supply Chain & Operational Excellence||
|HSBC Custody Nominees (Australia) Limited||30,209,511||45.95%|
|J P Morgan Nominees Australia Pty Limited||9,708,153||14.77%|
|Citicorp Nominees Pty Limited||3,911,642||5.95%|
|National Nominees Limited||1,606,824||2.44%|
|BNP Paribas Noms Pty Ltd <Drp>||1,570,432||2.39%|
|BNP Paribas Nominees Pty Ltd <Agency Lending Drp A/C>||1,166,640||1.77%|
|HSBC Custody Nominees (Australia) Limited GSCO ECA||645,315||0.98%|
|BNP Paribas Nominees Pty Ltd Six Sis Ltd <Drp A/C>||486,754||0.74%|
|HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C>||373,306||0.57%|
|Australian Foundation Investment Company Limited||324,174||0.49%|
|Netwealth Investments Limited <Wrap Services A/C>||258,114||0.39%|
|Citicorp Nominees Pty Limited <Colonial First State Inv A/C>||222,299||0.34%|
|Mr Christopher Graham Roberts||172,387||0.26%|
|BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <DRP A/C>||120,873||0.18%|
|Custodial Services Limited <Beneficiaries Holding A/C>||117,587||0.18%|
|HSBC Custody Nominees (Australia) Limited A/C 2||94,699||0.14%|
|AMP Life Limited||80,692||0.12%|
|BNP Paribas Nominees Pty Ltd Acf Clearstream||65,891||0.10%|
|National Nominees Limited <N A/C>||57,163||0.09%|
|BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp>||55,055||0.08%|
Cochlear typically pays twice yearly dividends in April and October. Over the past five years, the company’s dividends have all been fully franked. Prior to this, Cochlear’s dividends varied between fully franked and partially franked with only one dividend over this time being 100% unfranked. Cochlear’s last interim dividend of $1.60 per share was paid on 17 April 2020. The medical devices company has an impressive dividend payment history dating back to 1997. In March 2020, however, Cochlear withdrew its FY20 earnings guidance and announced a capital raising to enhance its liquidity. This was following the negative impacts of COVID-19 on its revenue streams. It also announced suspension of the company’s dividend until trading conditions improve.
At at 17 June 2020, Cochlear does not offer a dividend reinvestment plan.